Sequence 1 (FZD1 , FZD2 , FZD4 , FZD7 , FZD10 ( Homo sapiens ))

Sequence FZD1 , FZD2 , FZD4 , FZD7 , FZD10 ( Homo sapiens )
Target	FZD1 , FZD2 , FZD4 , FZD7 , FZD10 ( Homo sapiens )
Description	ENSG00000157240 7:91264364-91271326:1 Frizzled class receptor 1 ; ENSG00000180340 17:44557459-44559570:1 Frizzled class receptor 2 ; ENSG00000174804 11:86945679-86955391:-1 Frizzled class receptor 4 ; ENSG00000155760 2:202034587-202038445:1 Frizzled class receptor 7 ; ENSG00000111432 12:130162459-130165740:1 Frizzled class receptor 10
Design	peptide
Chemistry	amino acids
Sequence	FSVLYTVPAT
Application	multitargeting
Name	FZD1 , FZD2 , FZD4 , FZD7 , FZD10 ( Homo sapiens )

References

Identification of sequences common to more than one therapeutic target to treat complex diseases: simulating the high variance in sequence interactivity evolved to modulate robust phenotypes. Varela MA. BMC Genomics. 2015 Jul 18;16(1):530.

Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience. Hache M, Swoboda KJ, Sethna N, Farrow-Gillespie A, Khandji A, Xia S, Bishop KM. J Child Neurol. 2016 Jun;31(7):899-906. PubMed:26823478

Comments

Not experimentally validated , transmembrane

Background